The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Psoriasis Tied to Higher Risk of Serious Liver Disease

Psoriasis Tied to Higher Risk of Serious Liver Disease

November 13, 2017 • By Lisa Rapaport

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—People with chronic inflammatory disorders, such as psoriasis and rheumatoid arthritis (RA), may have an increased risk of developing serious liver damage, a recent study suggests.

You Might Also Like
  • Psoriatic Disease Linked to Higher Risk of Uveitis & Vice Versa
  • IBD Tied to Higher Risk of Invasive Pneumococcal Disease
  • Treating IBD with Anti-TNF Tied to Higher Risk of Demyelinating Disease

These inflammatory disorders are often treated with methotrexate, a medication linked to an increased risk of liver disease. For the current study, researchers followed more than 1 million people for an average of six years to see how having such conditions as psoriasis or RA—and taking methotrexate—influenced the odds of developing serious liver disorders.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Compared with people without chronic inflammatory diseases, people with psoriasis were 37% more likely to develop liver disorders. When psoriasis patients took methotrexate, they had roughly twice the odds of liver damage.

With psoriatic arthritis, the increased risk of liver disease was 38% without drug therapy and 67% with methotrexate. For rheumatoid arthritis, there was no increased risk of liver disease when people took methotrexate, but when they didn’t they had 49% higher odds of liver damage.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“This study is the first, to our knowledge, to empirically support the long held belief that psoriasis patients are more prone to serious liver problems compared with patients without psoriasis and those with diseases, such as rheumatoid arthritis, who are treated with similar medications,” says senior study author Dr. Joel Gelfand of the University of Pennsylvania Perelman School of Medicine in Philadelphia.

“Medications that are toxic to the liver, such as methotrexate, should be used cautiously in patients with psoriatic disease, especially those with additional risk factors such as obesity or regular alcohol use,” Gelfand says by email.

The study suggests systemic inflammation, which is present in all three diseases, may play a significant role in development of liver disease, particularly in those with psoriasis, researchers note online Nov. 2 in the Journal of Investigative Dermatology.1

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

For the study, researchers examined data on almost 1.3 million people without chronic inflammatory disorders, as well as roughly 198,000 psoriasis patients, 12,000 people with psoriatic arthritis and 54,000 with RA.

Among people with inflammatory disorders who took systemic therapy—medications that reach the whole body—methotrexate was the most commonly prescribed option.

Overall, 6% of psoriasis patients were prescribed systemic therapy, as were 53% of people with psoriatic arthritis and 61% of people with RA.

For independent risk factors commonly seen in liver disease, such as alcohol use and diabetes, the study found that patients with psoriatic skin or joint disease, particularly patients with more severe skin psoriasis, had an elevated risk for serious liver disease.

Pages: 1 2 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives, Drug Updates, Rheumatoid Arthritis Tagged With: liver, liver disease, metho­trexate, Psoriasis, Rheumatoid Arthritis (RA), skin

You Might Also Like:
  • Psoriatic Disease Linked to Higher Risk of Uveitis & Vice Versa
  • IBD Tied to Higher Risk of Invasive Pneumococcal Disease
  • Treating IBD with Anti-TNF Tied to Higher Risk of Demyelinating Disease
  • Some Jobs Tied to Higher Risk of RA

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.